Ixabepilone

Drug Profile

Ixabepilone

Alternative Names: Azaepothilone B; BMS-247550; Epothilone B analogue; Ixempra; Patupilone analogue

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator GBF
  • Developer Bristol-Myers Squibb
  • Class Antineoplastics; Epothilones; Macrolides; Small molecules
  • Mechanism of Action Cell cycle inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • No development reported Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer
  • Discontinued Cancer; Endometrial cancer; Prostate cancer

Most Recent Events

  • 17 Aug 2015 R-Pharm acquires ixabepilone from Bristol-Myers Squibb
  • 05 May 2015 Phase-II development for Breast cancer (Early-stage disease, Adjuvant therapy) is ongoing in Argentina, Asia, European Union, India, Peru, Philippines, Russia, South Korea and USA
  • 05 May 2015 Phase-III development for Breast cancer (Early-stage disease, Adjuvant therapy) is ongoing in USA and Puerto Rico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top